Synairgen (LON:SNG) Shares Down 9.5% – Should You Sell?

Synairgen plc (LON:SNG)’s share price dropped 9.5% during mid-day trading on Monday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 1.81 ($0.02). Approximately 129,056 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 1,508,068 shares. The stock had previously closed at GBX 2 ($0.03).

Synairgen Price Performance

The firm’s fifty day moving average is GBX 2.27 and its 200 day moving average is GBX 3.50. The firm has a market capitalization of £17.60 million, a price-to-earnings ratio of -1.08 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).